Peptide Receptor Radionuclide Therapy Plus Somatostatin Analogues for a Neuroendocrine Tumour Combined and Maintenance Treatment

Clinical and Translational Imaging - Italy
doi 10.1007/s40336-019-00342-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Joint Guidance on Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2013English

Peptide Receptor Radionuclide Therapy

Best Practice and Research in Clinical Gastroenterology
Gastroenterology
2005English

Peptide Receptor Radionuclide Therapy

2007English

Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2015English

New Developments in Peptide Receptor Radionuclide Therapy

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

Three-Dimensional Radiobiological Dosimetry of Kidneys for Treatment Planning in Peptide Receptor Radionuclide Therapy

Medical Physics
MedicineNuclear MedicineRadiologyImagingBiophysics
2012English

Reply: Peptide Receptor Radionuclide Therapy in the United States

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2012English

Neuroendocrine Neoplasms and Somatostatin Receptor Subtypes Expression

Nuclear Medicine Review
MedicineNuclear MedicineRadiologyImaging
2016English

68Ga-Dotatate PET/CT for the Early Prediction of Response to Somatostatin Receptor-Mediated Radionuclide Therapy in Patients With Well-Differentiated Neuroendocrine Tumors

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy